Deerfield Management’s Tempest Therapeutics TPST Stock Holding History

Deerfield Management’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-866	Closed	-$892K	–	103
2020 Q1	$892K	Buy	+866	New	+$1.26M	0.03%	86
2015 Q2	–	Sell	-139	Closed	-$14.1M	–	133
2015 Q1	$14.1M	Sell	139 -75	-35%	-$9.99M	0.46%	53
2014 Q4	$27.7M	Sell	214 -174	-45%	-$12.7M	1%	30
2014 Q3	$18.8M	Sell	388 -176	-31%	-$6.17M	0.69%	49
2014 Q2	$15.1M	Sell	564 -8	-1%	-$189K	0.61%	56
2014 Q1	$15M	Buy	572 +365	+176%	+$10.3M	0.61%	48
2013 Q4	$5.54M	Sell	207 -1	-0.5%	-$27.4K	0.29%	72
2013 Q3	$6.02M	Buy	208 +18	+9%	+$639K	0.28%	77
2013 Q2	$7.63M	Buy	+190	New	+$7.14M	0.36%	71

Other funds holding TPST

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Deerfield Management's TPST Position: Q2 2020 in Review

Deerfield Management sold out of Tempest Therapeutics (TPST) in Q2 2020, closing a stake of 866 shares — an estimated $892K sold.

Deerfield Management first reported a position in TPST in Q2 2013 and held it in 9 quarters. The position peaked at $27.7M in Q4 2014. 51 funds tracked by Wall St. Rank hold TPST as of Q2 2020.

Deerfield Management reported no remaining Tempest Therapeutics position as of Q2 2020 after selling out during the quarter.
Deerfield Management sold 866 Tempest Therapeutics shares in Q2 2020, an estimated $892K.
Deerfield Management first reported a position in Tempest Therapeutics in Q2 2013 and held it in 9 quarters.
Deerfield Management's Tempest Therapeutics position peaked at $27.7M in Q4 2014.
51 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2020.

Based on Deerfield Management's 13F filing for Q2 2020, filed 14 Aug 2020.